Table 1.
PK parameters
| Apixaban 2.5 mg twice daily | D3 | HDF_D4 | D5 | D10 | HDF_D11 | D12 | D24 | HDF_D25 | D26 | P |
|---|---|---|---|---|---|---|---|---|---|---|
| AUC 0–12; ng·h/ml (CV) | 862 (51%) | 1030 (51%) | 998 (46%) | 962 (52%) | 920 (46%) | 1025 (39%) | 907 (44%) | 921 (42%) | 982 (33%) | 0.9 |
| Cmax;ng/ml (CV) | 102 (43%) | 103 (51%) | 111 (46%) | 115 (51%) | 103 (43%) | 110 (32%) | 100 (33%) | 97 (34%) | 114 (29%) | 0.9 |
| Tmax;h (CV) | 2.5 (51%) | 2.4 (28%) | 2.5 (54%) | 2.2 (60%) | 2.9 (64%) | 2.6 (32%) | 2.5 (57%) | 2.4 (60%) | 2 (41%) | 0.5 |
| Cmin;ng/ml (CV) | 57 (71%) | 74 (60%) | 66 (49%) | 82 (77%) | 63 (58%) | 68 (48%) | 67 (59%) | 69 (45%) | 71 (45%) | 0.7 |
| t1/2; h (CV) | 15 (47%) | 20 (54%) | 22 (53%) | 23 (54%) | 21 (63%) | 24 (41%) | 22 (69%) | 26 (68%) | 22 (44%) | 0.14 |
| Creatinine clearance; ml/min (CV) | 0.35 (52%) | 0.15 (41%) | 0.25 (51%) | 0.2 (30%) | 0.05 (28%) | 0.17 (95%) | 0.17 (64%) | 0.1 (76%) | 0.11 (33%) | 0.048 |
| AI from 1st week (CV) | N/A | N/A | N/A | 1.13 (23%) | 0.95 (31%) | 1.07 (22%) | 1.12 (34%) | 0.98 (28%) | 1.07 (28%) | 0.6 |
| AI from 2nd week (CV) | N/A | N/A | N/A | N/A | N/A | N/A | 0.99 (26%) | 1.07 (27%) | 1.01 (22%) | 0.8 |
AI, accumulation index; AUC0–12, area under plasma concentration-time from 0 to 12 h after morning dose; Cmax, maximum observed plasma concentration; Cmin, minimum observed plasma concentration; CV, coefficient of variation expressed as a percentage; HDF, hemodiafiltration, N/A: not applicable; t½, terminal half-life; Tmax, time to peak apixaban concentration.
P was calculated using a paired t-test between days 4 and day 25.
The P-value for creatinine clearance and AI were calculated using analysis of variance.
Results are expressed as mean (% CV).